We are live on ! Find out more
CV

Clarus Ventures Portfolio holdings

AUM $425M
1-Year Est. Return 26.13%
This Fund
S&P 500
This Quarter Est. Return
+2.35%
1 Year Est. Return
+26.13%
3 Year Est. Return
+70.29%
5 Year Est. Return
+162.11%
10 Year Est. Return
–
AUM
$134M
AUM Growth
-$17.5M
Cap. Flow
-$10.2M
Cap. Flow %
-7.59%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSTG
1
DELISTED
NanoString Technologies, Inc.
NSTG
$78.7M 58.56%
3,959,440
– –
SIEN
2
DELISTED
Sientra, Inc.
SIEN
$23M 17.11%
273,077
– –
VBIV
3
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$14.8M 11%
89,701
– –
OXFD
4
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$6.89M 5.13%
445,093
-714,332
-62% -$10.2M
EPIX
5
DELISTED
ESSA Pharma
EPIX
$6.62M 4.93%
106,061
– –
ATXS
6
DELISTED
Astria Therapeutics
ATXS
$4.4M 3.28%
45,875
– –

Similar funds

LLC
Latimer Light Capital New York $432M AUM 25.5% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
SPC
Salient Private Client Houston, Texas $513M AUM 10.97% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
CG
Clinton Group New York $279M AUM 4.76% 1-Year Est. Return
AAM
Amerigo Asset Management George Town, Cayman Islands $254M AUM 115.73% 1-Year Est. Return
SE
Summit Equities Parsippany, New Jersey $601M AUM 9.74% 1-Year Est. Return
CA
Cynosure Advisors Salt Lake City, Utah $238M AUM 4% 1-Year Est. Return

Clarus Ventures's Q1 2017 Portfolio in Review

As of Q1 2017, Clarus Ventures held 6 positions worth $134M, down 12% from $152M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Clarus Ventures withdrew a net $10.2M in Q1 2017, reducing 1 holding. Its largest reduction was Oxford Immunotec Global PLC Ordinary Shares, cutting an estimated $10.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Clarus Ventures's biggest Q1 2017 reduction was Oxford Immunotec Global PLC Ordinary Shares, cutting an estimated $10.2M.
  • Clarus Ventures's ten largest holdings make up 100% of its $134M portfolio in Q1 2017.
  • Clarus Ventures opened 0 new positions and closed 0 in Q1 2017.
  • Clarus Ventures's portfolio value fell 12% quarter-over-quarter to $134M.

Based on Clarus Ventures's 13F filing for Q1 2017, filed 9 May 2017.